No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BLUE bluebird bio
- 1.020
- +0.067+7.03%
Close Apr 19 16:00 ET
- 1.020
- 0.0000.00%
Post 19:13 ET
196.60MMarket Cap-1619P/E (TTM)
1.030High0.940Low8.18MVolume0.950Open0.953Pre Close7.98MTurnover4.26%Turnover RatioLossP/E (Static)192.74MShares5.53052wk High0.88P/B195.68MFloat Cap0.87952wk Low--Dividend TTM191.84MShs Float152.883Historical High--Div YieldTTM9.44%Amplitude0.879Historical Low0.975Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Cerebral Adrenoleukodystrophy Pipeline Insight 2024, Featuring Key Players Minoryx Therapeutics, POXEL, Orpheris and Bluebird Bio
Express News | Bluebird Bio Inc Anticipates It Will Be Delayed In Filing Its Quarterly Report On Form 10-Q For Q1 Of 2024
Express News | bluebird bio Shares Down 9% at $0.90 After the Bell Following Announcement of Delay in 10-Q Filing
Express News | bluebird bio Inc - Anticipates It Will Be Delayed in Filing Its Quarterly Report on Form 10-Q for the First Quarter of 2024
TD Cowen Says Sickle Cell Therapies May Get Higher CMS Payments
Express News | Watching Bluebird Bio; Shares Spike Higher As Traders Circulating Unconfirmed Rumor Suggesting "Lyfgenia Is Among 8 New Therapies In The Running To Receive NTAP Designations At The Start Of FY25. The Emphasis On Supporting Access For SCD Therapies Across
Comments
Rumor spike?
$bluebird bio(BLUE.US$ Watching Bluebird Bio; Shares Spike Higher As Traders Circulating Unconfirmed Rumor Suggesting "Lyfgenia Is Among 8 New Therapies In The Running To Receive NTAP Designations At The Start Of FY25. The Emphasis On Supporting Access For SCD Therapies Across HHS Leaves Little Doubt That The New Therapy Will Qualify"
3
2
$bluebird bio(BLUE.US$
NEWS
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
bluebird bio, Inc. (BLUE) approved inducement grants of 102,700 RSUs to twelve new employees. The RSUs vest equally over four years, in line with NASDAQ rules.
NEWS
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
bluebird bio, Inc. (BLUE) approved inducement grants of 102,700 RSUs to twelve new employees. The RSUs vest equally over four years, in line with NASDAQ rules.
$bluebird bio(BLUE.US$ Accounting errors they say caused the restatement! So who pays for people’s losses because they went with the original numbers? Hehehe
1
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
72812736 : 一通狂涨，又跌回来了
TrytosaveabitOP 72812736: Shorts took advantage of the PI and not enough volume to keep the buy pressure on it!